Cargando…
Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data
BACKGROUND: Myasthenia gravis (MG) is a rare chronic autoimmune disease caused by autoantibodies directed against postsynaptic antigens of the neuromuscular junction. Over the last decades, increasing incidence and prevalence rates have been reported. Epidemiological data on prevalence and incidence...
Autores principales: | Wartmann, Hannes, Hoffmann, Sarah, Ruck, Tobias, Nelke, Christopher, Deiters, Barthold, Volmer, Timm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129022/ https://www.ncbi.nlm.nih.gov/pubmed/36807212 http://dx.doi.org/10.1159/000529583 |
Ejemplares similares
-
Bilateral Vocal Fold Paralysis in Myasthenia Gravis: A Case Report and Literature Review
por: Nelke, Christopher, et al.
Publicado: (2020) -
Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2023) -
Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data
por: Knapp, Rachel K., et al.
Publicado: (2021) -
Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022) -
Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2022)